Articles from Ceribell
SUNNYVALE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended March 31, 2025.
By Ceribell · Via GlobeNewswire · May 8, 2025
SUNNYVALE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming Bank of America Securities 2025 Health Care Conference. The presentation will take place on Wednesday, May 14, 2025, at 10:55 a.m. Pacific Standard Time / 1:55 p.m. Eastern Standard Time.
By Ceribell · Via GlobeNewswire · April 30, 2025

Ceribell is one of only 51 companies in the U.S. to achieve FedRAMP High authorization
By Ceribell · Via GlobeNewswire · April 30, 2025
SUNNYVALE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the first quarter of 2025 after the close of trading on Thursday, May 8, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on May 8, 2025.
By Ceribell · Via GlobeNewswire · April 24, 2025
Powered by Clarity, the Ceribell System will enable rapid, bedside detection, diagnosis and treatment of non-convulsive seizures in children experiencing neurological emergencies
By Ceribell · Via GlobeNewswire · April 15, 2025

SUNNYVALE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the fourth quarter and full year ended December 31, 2024.
By Ceribell · Via GlobeNewswire · February 25, 2025

SUNNYVALE, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, and Scott Blumberg, CFO, will participate in a fireside chat at the upcoming 45th Annual TD Cowen Health Care Conference. The fireside chat will take place on Monday, March 3, 2025, at 6:50 a.m. Pacific Standard Time / 9:50 a.m. Eastern Standard Time.
By Ceribell · Via GlobeNewswire · February 18, 2025

SUNNYVALE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the fourth quarter and full year of 2024 after the close of trading on Tuesday, February 25, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on February 25, 2025.
By Ceribell · Via GlobeNewswire · February 11, 2025

SUNNYVALE, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Ceribell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Monday, January 13, 2025, at 7:30 a.m. Pacific Standard Time.
By Ceribell · Via GlobeNewswire · December 23, 2024

—Ms. Rodenbush to lead hiring and talent development initiatives—
By Ceribell · Via GlobeNewswire · November 19, 2024

SUNNYVALE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended September 30, 2024.
By Ceribell · Via GlobeNewswire · November 12, 2024

—Ceribell System stands to reduce costly ICU admissions and intra-facility patient transfers—
By Ceribell · Via GlobeNewswire · November 11, 2024

SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. The fireside chat will take place on Thursday, November 21, 2024, at 10:00 a.m. Pacific Standard Time / 1:00 p.m. Eastern Standard Time.
By Ceribell · Via GlobeNewswire · November 7, 2024